

Maria R Baer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6940652/publications.pdf>

Version: 2024-02-01

142
papers

7,925
citations

94433

37
h-index

49909

87
g-index

143
all docs

143
docs citations

143
times ranked

8446
citing authors

#	ARTICLE	IF	CITATIONS
1	Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1340-1349.	0.9	5
2	Primary myelofibrosis in a patient with sickle cell disease. <i>American Journal of Hematology</i> , 2022, 97, 160-161.	4.1	1
3	PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers. <i>Translational Oncology</i> , 2022, 15, 101283.	3.7	7
4	Gastrointestinal Vasooclusive Crisis in a Woman with Hemoglobin SC Disease. <i>American Journal of Medicine</i> , 2022, , .	1.5	0
5	Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 1313-1322.	7.0	16
6	Disseminated histoplasmosis mimicking hematologic malignancy in a patient with human immunodeficiency virus. <i>EJHaem</i> , 2022, 3, 545-546.	1.0	2
7	SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome- <i>“</i> Negative B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 1574-1582.	1.6	44
8	Activating STING1-dependent immune signaling in <i><i>TP53</i></i> mutant and wild-type acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	9
9	PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition- <i>“</i> Dependent GSK-3 β - <i>“</i> Mediated c-Myc and Pim-1 Proteasomal Degradation. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 676-690.	4.1	10
10	FLT3-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification. <i>Biology</i> , 2021, 10, 243.	2.8	1
11	Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 817-826.	2.3	4
12	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. <i>Blood</i> , 2021, 138, 11-22.	1.4	90
13	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 387-400.	1.4	26
14	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431.	4.1	4
15	Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication. <i>Oncotarget</i> , 2021, 12, 1763-1779.	1.8	2
16	Increased body mass index is a risk factor for acute promyelocytic leukemia. <i>EJHaem</i> , 2021, 2, 33-39.	1.0	5
17	Novel BRCA2 c.8434_8435insTT (p. Gly2812Valfs*10) mutation in a family with multiple hematologic malignancies and solid tumors. <i>Leukemia and Lymphoma</i> , 2021, 62, 1275-1277.	1.3	3
18	Pim Kinase Inhibitor Enhances FLT3 Inhibitor Efficacy through GSK-3 β Activation and GSK-3 β -Mediated Proteasomal Degradation of c-Myc. <i>Blood</i> , 2021, 138, 1163-1163.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Aspartate Î²-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target. <i>Frontiers in Oncology</i> , 2021, 11, 783744.	2.8	2
20	Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 74-92.	0.9	17
21	Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 881-887.	2.5	7
22	An unusual presentation of paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2020, 188, 347-347.	2.5	1
23	Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. <i>Annals of Hematology</i> , 2020, 99, 2119-2124.	1.8	7
24	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions. <i>Blood Cancer Discovery</i> , 2020, 1, 48-67.	5.0	30
25	Clustered incidence of adult acute promyelocytic leukemia in the vicinity of Baltimore. <i>Leukemia and Lymphoma</i> , 2020, 61, 2743-2747.	1.3	0
26	Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. <i>Pharmaceuticals</i> , 2020, 13, 124.	3.8	5
27	Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1Î± with echinomycin. <i>Oncogene</i> , 2020, 39, 3015-3027.	5.9	25
28	Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study. <i>Blood</i> , 2020, 136, 55-57.	1.4	40
29	Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial. <i>Blood</i> , 2020, 136, 27-30.	1.4	3
30	Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report. <i>Cureus</i> , 2020, 12, e10507.	0.5	0
31	Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2020, 136, 37-38.	1.4	0
32	Hypomethylating Agent Therapy for Chronic Myelomonocytic Leukemia Does Not Impact Acute Myeloid Leukemia Transformation or Survival. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
33	Cryptic ETV6- <i>PDGFRB</i> fusion in a highly complex rearrangement of chromosomes 1, 5, and 12 due to a chromothripsis-like event in a myelodysplastic syndrome/myeloproliferative neoplasm. <i>Leukemia and Lymphoma</i> , 2019, 60, 1304-1307.	1.3	8
34	Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3577-3580.	1.3	1
35	Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML. <i>New England Journal of Medicine</i> , 2019, 381, 1728-1740.	27.0	796
36	Babesiosis Masquerading as Evans Syndrome. <i>American Journal of Medicine</i> , 2019, 132, e616-e617.	1.5	1

#	ARTICLE	IF	CITATIONS
37	Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib. <i>Acta Haematologica</i> , 2019, 141, 107-110.	1.4	14
38	Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment. <i>Advances in Cancer Research</i> , 2019, 141, 213-253.	5.0	11
39	Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism. <i>Acta Haematologica</i> , 2019, 142, 233-238.	1.4	14
40	Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1105-1112.	2.3	12
41	Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD. <i>Cancer Letters</i> , 2019, 454, 171-178.	7.2	14
42	FLT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 67-88.		2
43	Jumping translocations of chromosome 1q occurring by a multi-stage process in an acute myeloid leukemia progressed from myelodysplastic syndrome with a TET2 mutation. <i>Molecular Cytogenetics</i> , 2019, 12, 47.	0.9	1
44	Treatment of CD19 ⁺ positive mixed phenotype acute leukemia with blinatumomab. <i>American Journal of Hematology</i> , 2019, 94, E7-E8.	4.1	19
45	Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial. <i>Blood</i> , 2019, 134, 175-175.	1.4	8
46	A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity. <i>Blood</i> , 2019, 134, 4141-4141.	1.4	1
47	Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial. <i>Blood</i> , 2019, 134, 2145-2145.	1.4	1
48	An Electronic Teaching Module for Improving Knowledge of Self-Management of Vaso-Occlusive Pain Crises in Patients With Sickle Cell Disease: Pilot Questionnaire Study. <i>JMIR MHealth and UHealth</i> , 2019, 7, e13501.	3.7	2
49	DNA Methyltransferase Inhibitors Promote Homologous Recombination Deficiency through Induction of Immune Signaling, Sensitizing Acute Myeloid Leukemia Cells to PARP Inhibitors. <i>Blood</i> , 2019, 134, 3763-3763.	1.4	0
50	Acute Onset Unilateral Proptosis. <i>American Journal of Medicine</i> , 2018, 131, e337-e338.	1.5	0
51	Thrombotic microangiopathy in the setting of human immunodeficiency virus infection: High incidence of severe thrombocytopenia. <i>Journal of Clinical Apheresis</i> , 2018, 33, 342-348.	1.3	7
52	Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation. <i>Clinical Cancer Research</i> , 2018, 24, 234-247.	7.0	34
53	High-risk acute promyelocytic leukemia with unusual T/myeloid immunophenotype successfully treated with ATRA and arsenic trioxide-based regimen. <i>Journal of Hematopathology</i> , 2018, 11, 67-74.	0.4	5
54	Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. <i>Blood Advances</i> , 2018, 2, 1645-1650.	5.2	85

#	ARTICLE	IF	CITATIONS
55	Sickle Cell Disease Complicated by Iron Overload: An Under-Recognized Risk Factor for <i>Vibrio vulnificus</i> Infection. <i>Acta Haematologica</i> , 2018, 139, 199-200.	1.4	4
56	Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. <i>Journal of Hematology and Oncology</i> , 2018, 11, 101.	17.0	20
57	Novel t(5;11)(q32;q13.4) with NUMA1 - PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate. <i>Cancer Genetics</i> , 2017, 212-213, 38-44.	0.4	6
58	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1/2 study. <i>Lancet Oncology</i> , 2017, 18, 1061-1075.	10.7	402
59	FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 991-1001.	4.1	223
60	Use of the APACHE II score to assess impact of therapeutic plasma exchange for critically ill patients with hypertriglyceride-induced pancreatitis. <i>Transfusion and Apheresis Science</i> , 2017, 56, 123-126.	1.0	20
61	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 697-706.	7.0	56
62	A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. <i>Blood Advances</i> , 2017, 1, 331-340.	5.2	57
63	Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2. <i>Pharmaceuticals</i> , 2016, 9, 4.	3.8	9
64	Development of Hypercalcemia in a Patient Receiving Peginterferon alfa-2a Therapy for Polycythemia Vera. <i>Pharmacotherapy</i> , 2016, 36, e54-e57.	2.6	1
65	Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer. <i>Cancer Cell</i> , 2016, 30, 637-650.	16.8	151
66	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 374-377.	0.9	7
67	Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. <i>Oncotarget</i> , 2016, 7, 48280-48295.	1.8	16
68	Patient Cost Sharing and Receipt of Erythropoiesis-Stimulating Agents Through Medicare Part D. <i>Journal of Oncology Practice</i> , 2015, 11, e190-e198.	2.5	4
69	c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias. <i>Molecular Cancer Research</i> , 2015, 13, 699-712.	3.4	55
70	Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response. <i>Leukemia Research</i> , 2015, 39, 586-591.	0.8	8
71	The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations. <i>Investigational New Drugs</i> , 2015, 33, 300-309.	2.6	22
72	Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: A single center study. <i>Cancer</i> , 2015, 121, 1064-1070.	4.1	37

#	ARTICLE	IF	CITATIONS
73	Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. <i>Leukemia and Lymphoma</i> , 2015, 56, 1718-1722.	1.3	18
74	Racial Differences in Molecular Cytogenetic Abnormalities in Black and White Patients with Multiple Myeloma (MM): A Single-Center Experience. <i>Blood</i> , 2015, 126, 1767-1767.	1.4	0
75	High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication. <i>Cancer Genetics</i> , 2014, 207, 467-473.	0.4	10
76	Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2014, 55, 1533-1537.	1.3	45
77	Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. <i>Leukemia</i> , 2014, 28, 1754-1758.	7.2	24
78	GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. <i>Leukemia</i> , 2014, 28, 1252-1258.	7.2	45
79	Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. <i>Oncology Reports</i> , 2014, 31, 1605-1612.	2.6	26
80	Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs). <i>Blood</i> , 2014, 124, 163-163.	1.4	12
81	Effect of Erythropoiesis-Stimulating Agent Policy Decisions on Off-Label Use in Myelodysplastic Syndromes. <i>Medicare & Medicaid Research Review</i> , 2014, 4, E1-E16.	1.3	8
82	Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs). <i>Blood</i> , 2014, 124, 3259-3259.	1.4	0
83	MiR-300 Acts As a Tumor Suppressor in Ph ⁺ Progenitors By Modulating the JAK2-SET/PP2A ¹ -Catenin Interplay. <i>Blood</i> , 2014, 124, 4529-4529.	1.4	0
84	Outcome of older patients with acute myeloid leukemia. <i>Cancer</i> , 2013, 119, 2720-2727.	4.1	175
85	<i>Scedosporium apiospermum</i> Soft Tissue Infection As the Initial Presentation of Acute Myeloid Leukemia: A Case Report. <i>Journal of Clinical Oncology</i> , 2013, 31, e98-e100.	1.6	8
86	Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience. <i>Leukemia and Lymphoma</i> , 2013, 54, 304-309.	1.3	12
87	Dimeric Naphthoquinones: Novel Anti-Leukemic Agents Modulating Cellular Redox Status. <i>Blood</i> , 2013, 122, 1290-1290.	1.4	2
88	Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001). <i>Blood</i> , 2013, 122, 2653-2653.	1.4	3
89	A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium. <i>Blood</i> , 2013, 122, 386-386.	1.4	18
90	The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions. <i>PLoS ONE</i> , 2013, 8, e71266.	2.5	28

#	ARTICLE	IF	CITATIONS
91	Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication. <i>PLoS ONE</i> , 2013, 8, e74653.	2.5	59
92	C-MYC and C-MYC-Regulated Micrnas Increase The Activity Of The Error-Prone ALT NHEJ Pathway Through Upregulation Of LIG3 and PARP1 In Tyrosine Kinase-Activated Leukemias. <i>Blood</i> , 2013, 122, 809-809.	1.4	0
93	Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). <i>Blood</i> , 2013, 122, 2540-2540.	1.4	0
94	Demethylating Agents Reprogram Myelodysplastic Syndrome and Leukemia Cells, Sensitizing Them To Poly-(ADP)-Ribose Polymerase Inhibitors. <i>Blood</i> , 2013, 122, 3778-3778.	1.4	0
95	The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2033-2044.	4.1	81
96	Drug resistance: Still a daunting challenge to the successful treatment of AML. <i>Drug Resistance Updates</i> , 2012, 15, 62-69.	14.4	218
97	Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 4515-4523.	1.6	363
98	Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 742-750.	1.6	244
99	Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: A single-institution experience. <i>Leukemia Research</i> , 2012, 36, 140-145.	0.8	33
100	Rare hemoglobinopathy presenting as progressive dyspnea: Response to letter. <i>American Journal of Hematology</i> , 2012, 87, 132-132.	4.1	0
101	Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. <i>Leukemia and Lymphoma</i> , 2011, 52, 1211-1214.	1.3	27
102	Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1796-1803.	2.0	123
103	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. <i>Blood</i> , 2011, 117, 3294-3301.	1.4	353
104	Novel Agents for the Treatment of Acute Myeloid Leukemia in the Older Patient. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 331-335.	4.9	15
105	Upfront Therapy of Acute Myeloid Leukemia. <i>Current Oncology Reports</i> , 2011, 13, 361-370.	4.0	2
106	Effects of Toll-like receptor signals in T-cell neoplasms. <i>Future Oncology</i> , 2011, 7, 309-320.	2.4	9
107	P-glycoprotein inhibition using valsopodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. <i>Blood</i> , 2010, 116, 1413-1421.	1.4	113
108	FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010, 116, 3622-3626.	1.4	201

#	ARTICLE	IF	CITATIONS
109	Littoral cell angioma: A correctable cause of progressive pancytopenia in a patient with myelodysplastic syndrome. <i>Leukemia Research</i> , 2010, 34, e117-e119.	0.8	1
110	<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2348-2355.	1.6	699
111	Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 338-341.	1.3	12
112	Pim-1 Kinase Protects P-Glycoprotein from Degradation and Enables Its Glycosylation and Cell Surface Expression. <i>Molecular Pharmacology</i> , 2010, 78, 310-318.	2.3	85
113	Favorable Prognostic Impact of <i>NPM1</i> Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 596-604.	1.6	305
114	Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3842-3848.	1.6	321
115	Is there a role for maintenance therapy in acute myeloid leukaemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 517-521.	1.7	8
116	Black Patients with Acute Myeloid Leukemia (AML) Are Younger and More Commonly Female, but Have a Higher Incidence of Complex Karyotypes When Compared to Whites.. <i>Blood</i> , 2009, 114, 2649-2649.	1.4	7
117	Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: Possible role of cytarabine. <i>Leukemia Research</i> , 2008, 32, 1043-1048.	0.8	22
118	Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: Increased frequency of other cancers and of cancers in multiple family members. <i>Leukemia Research</i> , 2008, 32, 1820-1823.	0.8	7
119	T/B and not T/B: High frequency of B-cell dyscrasias in T-LGL leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 845-846.	1.3	2
120	Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720. <i>Journal of Clinical Oncology</i> , 2008, 26, 4934-4939.	1.6	114
121	Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. <i>Blood</i> , 2006, 108, 63-73.	1.4	285
122	Rare Leukemias. , 2006, , 543-554.		0
123	Isochromosome 1q in a myelodysplastic syndrome after treatment for acute promyelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2006, 167, 155-160.	1.0	13
124	Efficacy of Decitabine in the Treatment of Patients with Chronic Myelomonocytic Leukemia (CMML).. <i>Blood</i> , 2006, 108, 2676-2676.	1.4	1
125	Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT).. <i>Blood</i> , 2006, 108, 3033-3033.	1.4	0
126	Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 482-493.	1.6	119

#	ARTICLE	IF	CITATIONS
127	The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.. Blood, 2005, 106, 1512-1512.	1.4	1
128	Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood, 2004, 103, 4036-4042.	1.4	96
129	Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood, 2002, 100, 1224-1232.	1.4	335
130	Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry, 2002, 48, 59-65.	1.8	75
131	Detection of minimal residual disease in acute myeloid leukemia. Current Oncology Reports, 2002, 4, 398-402.	4.0	9
132	Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood, 2002, 100, 1224-32.	1.4	105
133	Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clinical Cancer Research, 2002, 8, 2812-9.	7.0	40
134	High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis. American Journal of Hematology, 2001, 67, 119-124.	4.1	11
135	Uncommon patterns of presentation of leukemia. , 1999, 17, 11-29.		10
136	Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered. Journal of Clinical Oncology, 1999, 17, 3767-3775.	1.6	290
137	Interferon- γ -associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer, 1998, 83, 1938-1946.	4.1	45
138	Neutropenia Associated With T-Cell Large Granular Lymphocyte Leukemia: Long-Term Response to Cyclosporine Therapy Despite Persistence of Abnormal Cells. Blood, 1998, 91, 3372-3378.	1.4	101
139	Interferon- γ -associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer, 1998, 83, 1938-1946.	4.1	3
140	Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22). Blood, 1997, 90, 1643-1648.	1.4	5
141	High Dose Cytosine Arabinoside, Idarubicin and G-CSF Therapy for De Novo and Secondary Adult Acute Myeloid Leukemia. Leukemia and Lymphoma, 1992, 7, 8-10.	1.3	2
142	Normal full-term pregnancy in a patient with chronic myelogenous leukemia treated with γ -interferon. American Journal of Hematology, 1991, 37, 66-66.	4.1	21